Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.34 |
| ▸ | AR | P10275 | 4/20 | 0.33 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.33 |
| ▸ | SLC27A1 | Q6PCB7 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15520159 | 0.82 | HCRTR1 (0.38) | GRIA1HCRTR1HCRTR2HCAR2SLC27A1 | |
| SCHEMBL13933900 | 0.81 | HCRTR1 (0.40) | GRIA1HCRTR1HCRTR2HCAR2AR | |
| SCHEMBL18611527 | 0.80 | GRIA1 (0.40) | GRIA1HCRTR1HCRTR2HCAR2AR | |
| SCHEMBL13933901 | 0.80 | GRIA1 (0.37) | GRIA1HCRTR1HCRTR2HCAR2AR | |
| SCHEMBL15519476 | 0.78 | AR (0.41) | GRIA1HCRTR1HCRTR2HCAR2AR | |
| SCHEMBL15520488 | 0.78 | HCAR2 (0.37) | GRIA1HCRTR1HCRTR2HCAR2AR | |
| SCHEMBL15603543 | 0.78 | KDM5A (0.40) | GRIA1HCRTR1HCRTR2HCAR2AR | |
| SCHEMBL15520187 | 0.77 | GRIA1 (0.40) | GRIA1HCRTR1HCRTR2KCNJ1SLC27A1 | |
| Hydrochloric Acid SCHEMBL15520216 | 0.77 | HCAR2 (0.37) | GRIA1HCRTR1HCRTR2HCAR2AR | |
| SCHEMBL15519258 | 0.76 | HCAR2 (0.49) | GRIA1HCRTR1HCRTR2HCAR2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2862860-B1 | 1,3-OXAZOLIDINE OR 1,3-OXAZINANE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | TAISHO PHARMACEUTICAL CO LTD (JP) | 2016-12-21 | — | — | EP | disclosed |
| EP-2862860-B1 | 1,3-OXAZOLIDINE OR 1,3-OXAZINANE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | TAISHO PHARMACEUTICAL CO LTD (JP) | 2016-12-21 | — | — | EP | disclosed |
| US-9266870-B2 | Heteroaromatic methyl cyclic amine derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-02-23 | — | — | US | disclosed |
| US-9266870-B2 | Heteroaromatic methyl cyclic amine derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-02-23 | — | — | US | disclosed |
| US-9266870-B2 | Heteroaromatic methyl cyclic amine derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-02-23 | — | — | US | disclosed |
| US-20150183768-A1 | HETEROAROMATIC METHYL CYCLIC AMINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-02 | — | — | US | disclosed |
| US-20150183768-A1 | HETEROAROMATIC METHYL CYCLIC AMINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-02 | — | — | US | disclosed |
| US-20150183768-A1 | HETEROAROMATIC METHYL CYCLIC AMINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-02 | — | — | US | disclosed |
| EP-2862860-A1 | HETEROAROMATIC METHYL CYCLIC AMINE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2862860-A1 | HETEROAROMATIC METHYL CYCLIC AMINE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183768-A1 | HETEROAROMATIC METHYL CYCLIC AMINE DERIVATIVE | HCRTR2, HCRTR1, HTR2B | GRIA1 36/4885HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.